Protalix reports anti-Gaucher drug Phase III trial results
The double-blind, dose-ranging, multi-center, parallel group, randomized study was designed to evaluate the safety and efficacy of taliglucerase alfa in 31 treatment-naive patients suffering from Gaucher disease. Patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.